查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813955

类淀粉沉积症治疗市场规模、份额和趋势分析报告：按治疗、最终用途、地区和细分市场预测，2025-2033 年

Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care), By End Use ( Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

类淀粉沉积症治疗市场摘要

预计 2024 年全球类淀粉沉积症治疗市值为 58 亿美元，到 2033 年将达到 111.3 亿美元，2025 年至 2033 年的复合年增长率为 7.5%。

该行业的成长得益于人们对疾病认识的提高、诊断方法的进步以及由于诊断准确而得到早期诊断的患者数量的增加。

先进成像、质谱分析和基因检测等技术创新使医疗保健提供者能够更好地区类淀粉沉积症变性亚型，从而支持更精准有效的治疗方法。专科医疗中心的建立和训练有素的医疗专业人员的配备，进一步改善了综合治疗的可及性。此外，与老龄化相关的转甲状腺素类淀粉沉积症变性发病率不断上升，尤其是在老年族群中，这推动了对长期治疗方案的需求。类淀粉沉积症是一种可以透过及时治疗有效控制的疾病，这项认识正在改变全球患者照护实践。

推动类淀粉沉积症治疗市场的主要因素之一是针对转甲状腺素类淀粉沉积症基因静默疗法的监管收紧。例如，2025 年 3 月，美国FDA核准Amvuttra (vutrisiran) 作为首个针对转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM) 的基因静默疗法。此项核准基于 III 期 HELIOS-B 试验的结果，该结果显示全因死亡率和心血管事件减少了 28%。患者的功能能力和生活品质也得到了显着改善。这项进展提供了一种新的治疗途径，每年只需注射四次即可直接减少 TTR 蛋白的产生。预计此项核准将促进早期诊断，扩大基于 RNA 的治疗方法的采用，并加剧 ATTR-CM 市场的竞争。

针对转甲状腺素类淀粉沉积症的高效小分子稳定剂已获得监管部门核准，是推动类淀粉沉积症治疗市场发展的重大进展。例如，2024年12月，美国FDA核准了BridgeBio Pharma开发的近乎完全的转甲状腺素蛋白(TTR)稳定剂Attruvy (Acoramidis)，用于治疗心肌病(ATTR-CM)。在关键的ATTRibute-CM试验中，Acoramidis显示出超过90%的TTR稳定性，并显着降低了心血管死亡和住院率。此次核准拓宽了RNAi治疗方法以外的治疗选择，引入了一种方便的口服替代方案，可满足更广泛患者群体的需求。预计这将加剧市场竞争并加速ATTR-CM治疗的技术创新。凭藉更高的疗效、耐受性和易用性，Acoramidis有望重塑新诊断和长期ATTR-CM患者的治疗模式。

癌症患者数量快速成长，预计到2050年，美国将成长47.5%，加拿大将成长60.7%，这导致慢性疾病和多重併发症的盛行率上升。这一趋势凸显了医疗保健系统日益加重的负担，进而加速了先进诊断和治疗解决方案的需求。鑑于癌症和类淀粉沉积症在临床上面临共同挑战，包括器官功能障碍、蛋白质错误折迭和全身性炎症，癌症发病率的上升间接提高了人们对类淀粉沉积症等相关疾病的认识和识别。这种关联可能会推动患者筛检的增加、医疗保健投资的扩大以及治疗基础设施的增强。

因此，随着癌症发病率的上升推动临床认知和治疗创新，预计该行业将从这些动态中受益。精准医疗需求的不断增长，可能促使人们更加关注单株抗体、标靶治疗以及更有效控制疾病进展的支持性护理解决方案。此外，製药公司和医疗保健提供者可能会增加研究资金和合作，利用肿瘤学的进步来加速类淀粉沉积症的研究和开发。这些协同效应预计将在未来几十年推动类淀粉沉积症市场的显着成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章类淀粉沉积症治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章类淀粉沉积症治疗市场：治疗业务分析

  • 2024年和2033年的治疗市场份额
  • 治疗细分仪表板
  • 2021-2033 年治疗学市场规模、预测与趋势分析
  • 化疗
  • 免疫抑制剂
  • 移植
  • 支持性护理
  • 外科手术
  • 其他的

第五章类淀粉沉积症治疗市场：最终用途业务分析

  • 2024年和2033年的最终用途市场份额
  • 最终用途细分仪表板
  • 市场规模、预测与趋势分析（依最终用途，2021-2033 年）
  • 医院和诊所
  • 门诊手术中心
  • 居家照护环境
  • 其他的

第六章类淀粉沉积症治疗市场：区域估计与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场仪表板
  • 2021-2033年市场规模与预测趋势分析
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • GSK plc
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Merck KGaA
    • Sanofi
    • Alnylam Pharmaceuticals, Inc.
Product Code: GVR-2-68038-443-7

Amyloidosis Treatment Market Summary

The global amyloidosis treatment market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The industry is experiencing growth due to rising awareness of the disease, advancements in diagnostic methods, and an increasing number of patients being identified at earlier stages with accurate diagnoses.

Innovations such as advanced imaging, mass spectrometry, and genetic testing are allowing healthcare providers to better distinguish between amyloidosis subtypes, supporting more precise and effective treatment approaches. The establishment of specialized care centers and the availability of trained medical experts are further enhancing access to comprehensive care. Additionally, the growing incidence of age-related transthyretin amyloidosis, particularly among older populations, is driving demand for long-term therapeutic solutions. These factors are prompting pharmaceutical companies to expand their research pipelines, while the recognition of amyloidosis as a condition that can be effectively managed with timely treatment is transforming global patient care practices.

One of the key drivers fueling the amyloidosis treatment market is the regulatory advancement of gene-silencing therapies for transthyretin amyloidosis. For instance, in March 2025, the U.S. FDA approved Amvuttra (vutrisiran) as the first gene-silencing therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The approval was backed by Phase III HELIOS-B trial results showing a 28% reduction in all-cause mortality and cardiovascular events. Patients also experienced notable improvements in functional capacity and quality of life. This advancement offers a new treatment pathway directly reducing TTR protein production with only four annual injections. The approval is expected to boost early diagnosis, expand RNA-based therapy adoption, and intensify competition in the ATTR-CM market.

The regulatory approval of highly effective small-molecule stabilizers targeting transthyretin amyloidosis is a major development boosting the amyloidosis treatment market. For instance , in December 2024, the U.S. FDA approved Attruby (acoramidis), a near-complete transthyretin (TTR) stabilizer developed by BridgeBio Pharma, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) (BridgeBio). Acoramidis demonstrated over 90% stabilization of TTR and significantly reduced cardiovascular death and hospitalizations in the pivotal ATTRibute-CM trial. The approval introduces a convenient oral alternative that expands treatment options beyond RNAi-based therapies and meets the needs of a broader patient base. It is expected to intensify market competition and accelerate innovation in ATTR-CM therapeutics. With improved efficacy, tolerability, and ease of administration, acoramidis is positioned to reshape treatment paradigms for newly diagnosed and long-term ATTR-CM patients.

The projected surge in cancer cases, with the United States expected to see a 47.5% increase and Canada a 60.7% increase by 2050, the rising prevalence of chronic and complex diseases. This trend emphasizes the growing strain on healthcare systems, which in turn accelerates demand for advanced diagnostics and treatment solutions. Given that cancer and amyloidosis share overlapping clinical challenges such as organ dysfunction, protein misfolding, and systemic inflammation, the increase in cancer incidence indirectly raises awareness and identification of related conditions like amyloidosis. This linkage is likely to enhance patient screening, expand healthcare investments, and strengthen treatment infrastructure.

Consequently, the industry is expected to benefit from these dynamics as rising cancer prevalence fuels both clinical awareness and therapeutic innovation. With heightened demand for precision therapies, there will be an increased focus on monoclonal antibodies, targeted treatments, and supportive care solutions that address disease progression more effectively. Moreover, pharmaceutical companies and healthcare providers are likely to increase research funding and collaborations, leveraging advancements in oncology to accelerate drug development for amyloidosis. This synergy will position the amyloidosis market for significant growth in the coming decades.

Global Amyloidosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyloidosis treatment market report based on treatment, end-use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End-use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Amyloidosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Amyloidosis Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunosuppressive Drugs
    • 4.5.1. Immunosuppressive Drugs Market, 2021 - 2033 (USD Million)
  • 4.6. Transplantation
    • 4.6.1. Transplantation Market, 2021 - 2033 (USD Million)
  • 4.7. Supportive Care
    • 4.7.1. Supportive Care Market, 2021 - 2033 (USD Million)
  • 4.8. Surgery
    • 4.8.1. Surgery Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Amyloidosis Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 5.5. Ambulatory Surgical Centers
    • 5.5.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Home Care Settings
    • 5.6.1. Home Care Settings Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Amyloidosis Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 6.4. North America
    • 6.4.1. North America Amyloidosis Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Johnson & Johnson Services, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. GSK plc
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Takeda Pharmaceutical Company Limited
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Amgen Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bristol-Myers Squibb Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. F. Hoffmann-La Roche Ltd
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Merck KGaA
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Treatment Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Alnylam Pharmaceuticals, Inc.
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Treatment Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global amyloidosis treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 6 North America amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8 North America amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 9 U.S. amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 U.S. amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 11 Canada amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 Canada amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 13 Mexico amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14 Mexico amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 15 Europe amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17 Europe amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 18 UK amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 UK amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 20 Germany amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 22 France amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 France amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 24 Italy amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 26 Spain amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 28 Norway amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Norway amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 30 Denmark amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 Denmark amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 32 Sweden amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33 Sweden amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 37 Japan amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Japan amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 39 China amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 China amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 41 India amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42 India amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 43 Australia amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Australia amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 45 South Korea amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 South Korea amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 47 Thailand amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48 Thailand amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 49 Latin America amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Latin America amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 52 Brazil amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 54 Argentina amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55 Argentina amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 59 South Africa amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 South Africa amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 63 UAE amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64 UAE amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 Kuwait amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Amyloidosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and treatment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Amyloidosis treatment market dynamics
  • Fig. 12 Amyloidosis treatment market: Porter's five forces analysis
  • Fig. 13 Amyloidosis treatment market: PESTLE analysis
  • Fig. 14 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunosuppressive drugs market, 2021 - 2033 (USD Million)
  • Fig. 17 Transplantation market, 2021 - 2033 (USD Million)
  • Fig. 18 Supportive care market, 2021 - 2033 (USD Million)
  • Fig. 19 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 End use market, 2021 - 2033 (USD Million)
  • Fig. 22 Hospitals & clinics market, 2021 - 2033 (USD Million)
  • Fig. 23 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 24 Home care settings market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Amyloidosis treatment market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 70 MEA amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework